Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8536781 | 0.98 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1POLBCYP1A2 | |
| SCHEMBL20687603 | 0.98 | KMT2A (0.45) | KMT2AMEN1L3MBTL1POLBCYP1A2 | |
| SCHEMBL8560901 | 0.98 | KMT2A (0.49) | KMT2AMEN1L3MBTL1POLBCYP1A2 | |
| SCHEMBL8558768 | 0.98 | L3MBTL1 (0.47) | KMT2AMEN1L3MBTL1POLBCYP1A2 | |
| SCHEMBL8558755 | 0.96 | KMT2A (0.48) | KMT2AMEN1L3MBTL1POLBCYP1A2 | |
| SCHEMBL20687601 | 0.96 | KMT2A (0.48) | KMT2AMEN1L3MBTL1POLBCYP1A2 | |
| SCHEMBL20687602 | 0.96 | L3MBTL1 (0.46) | KMT2AMEN1L3MBTL1POLBCYP1A2 | |
| SCHEMBL20687600 | 0.94 | KMT2A (0.47) | KMT2AMEN1L3MBTL1POLBCYP1A2 | |
| SCHEMBL7937319 | 0.94 | KMT2A (0.51) | KMT2AMEN1POLBCYP1A2CHRM2 | |
| SCHEMBL8560898 | 0.93 | MEN1 (0.42) | KMT2AMEN1L3MBTL1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319301-B2 | Halogen complexes of compounds comprising at least one ether, thioether, and/or imine moiety and at least two lactam moieties | ISP INVESTMENTS LLC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20200231574-A1 | HALOGEN COMPLEXES OF COMPOUNDS COMPRISING AT LEAST ONE ETHER, THIOETHER, AND/OR IMINE MOIETY AND AT LEAST TWO LACTAM MOIETIES | ISP INVESTMENTS LLC (US) | 2020-07-23 | — | — | US | disclosed |
| WO-2019023453-A1 | HALOGEN COMPLEXES OF COMPOUNDS COMPRISING AT LEAST ONE ETHER, THIOETHER, AND/OR IMINE MOIETY AND AT LEAST TWO LACTAM MOIETIES | ISP INVESTMENTS LLC (US) | 2019-01-31 | — | — | WO | disclosed |
| US-9993559-B2 | N-alkyl lactam ethers, and compositions and uses thereof | ISP INVESTMENTS LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993559-B2 | N-alkyl lactam ethers, and compositions and uses thereof | ISP INVESTMENTS LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160271254-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271254-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-9351484-B2 | N-alkyl lactam ethers, and compositions and uses thereof | ISP INVESTMENTS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351484-B2 | N-alkyl lactam ethers, and compositions and uses thereof | ISP INVESTMENTS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140045698-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045698-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120148514-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148514-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012068001-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271254-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | USP8, MLST8, CYP2C8 | KMT2A 3225/4885MEN1 2038/4885L3MBTL1 4202/4885 |
| US-20140045698-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | USP8, MLST8, CYP2C8 | KMT2A 3225/4885MEN1 2038/4885L3MBTL1 4202/4885 |
| US-20120148514-A1 | N-ALKYL LACTAM ETHERS, AND COMPOSITIONS AND USES THEREOF | USP8, MLST8, CYP2C8 | KMT2A 3225/4885MEN1 2038/4885L3MBTL1 4202/4885 |
| US-11319301-B2 | Halogen complexes of compounds comprising at least one ether, thioether, and/or imine moiety and at least two lactam moieties | BTK, TBCD, INTS9 | KMT2A 1261/4885MEN1 665/4885L3MBTL1 1304/4885 |
| US-20200231574-A1 | HALOGEN COMPLEXES OF COMPOUNDS COMPRISING AT LEAST ONE ETHER, THIOETHER, AND/OR IMINE MOIETY AND AT LEAST TWO LACTAM MOIETIES | BTK, TBCD, INTS9 | KMT2A 1261/4885MEN1 665/4885L3MBTL1 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.